Abaloparatide vs BPC-157
Overview
Abaloparatide and BPC-157 are both bone & joint peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Abaloparatide and BPC-157 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Abaloparatide | BPC-157 | |
|---|---|---|
| Category | Bone & Joint | Bone & Joint |
| Regulatory status (US) | Research use only | Compounding (Rx) — Apr 2026 |
| Typical dosage | 80 mcg | 250-500 mcg |
| Frequency | daily | daily |
| Reported benefits | Bone building, osteoporosis treatment, reduced fracture risk | Accelerated bone healing, cartilage repair, joint support |
| Reported side effects | Similar to teriparatide but milder | Minimal side effects |
Key differences
Primary use. Abaloparatide is categorised under Bone & Joint, while BPC-157 falls under Bone & Joint. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Abaloparatide: not FDA-approved; treated as a research compound. BPC-157: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Abaloparatide is typically dosed at 80 mcg (daily). BPC-157 is typically dosed at 250-500 mcg (daily).
Can you stack them?
Some protocols combine peptides, but stacking Abaloparatide and BPC-157 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Abaloparatide and BPC-157?
- Abaloparatide and BPC-157 are both bone & joint peptides, but they differ in mechanism, dosing, and regulatory status. Abaloparatide is not FDA-approved; generally classified as a research compound, whereas BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Abaloparatide used for?
- Advanced bone anabolic.
- What is BPC-157 used for?
- Bone and cartilage healing.
- Can you take Abaloparatide and BPC-157 together?
- Some users combine peptides within a single protocol, but stacking Abaloparatide and BPC-157 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Abaloparatide or BPC-157 FDA-approved?
- Abaloparatide is not FDA-approved; generally classified as a research compound. BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Abaloparatide — full monograph: mechanism, research, dosing & references
- BPC-157 — full monograph: mechanism, research, dosing & references